Mariner LLC Increases Stake in The Cooper Companies, Inc. (NASDAQ:COO)

Mariner LLC grew its stake in The Cooper Companies, Inc. (NASDAQ:COO) by 10.4% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 34,142 shares of the medical device company’s stock after buying an additional 3,220 shares during the period. Mariner LLC’s holdings in Cooper Companies were worth $3,139,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Norges Bank purchased a new stake in Cooper Companies in the fourth quarter valued at approximately $217,906,000. FMR LLC raised its holdings in shares of Cooper Companies by 97.6% during the fourth quarter. FMR LLC now owns 2,218,112 shares of the medical device company’s stock worth $203,911,000 after purchasing an additional 1,095,805 shares during the last quarter. Raymond James Financial Inc. acquired a new position in Cooper Companies during the fourth quarter valued at $64,826,000. Victory Capital Management Inc. grew its position in Cooper Companies by 14.6% during the 4th quarter. Victory Capital Management Inc. now owns 4,525,018 shares of the medical device company’s stock worth $415,985,000 after purchasing an additional 574,899 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in shares of Cooper Companies by 13.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 4,930,022 shares of the medical device company’s stock valued at $543,979,000 after buying an additional 573,908 shares during the last quarter. 24.39% of the stock is currently owned by institutional investors and hedge funds.

Cooper Companies Stock Down 1.0 %

Shares of COO opened at $78.70 on Tuesday. The stock has a 50 day moving average price of $82.79 and a 200 day moving average price of $93.29. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.12 and a current ratio of 1.91. The stock has a market capitalization of $15.74 billion, a price-to-earnings ratio of 40.36, a PEG ratio of 2.25 and a beta of 1.01. The Cooper Companies, Inc. has a one year low of $69.81 and a one year high of $112.38.

Cooper Companies (NASDAQ:COO) last issued its earnings results on Thursday, March 6th. The medical device company reported $0.92 EPS for the quarter, meeting analysts’ consensus estimates of $0.92. The business had revenue of $964.70 million during the quarter, compared to analysts’ expectations of $981.25 million. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. Equities research analysts forecast that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Robert W. Baird reduced their price target on Cooper Companies from $117.00 to $107.00 and set an “outperform” rating for the company in a research report on Friday, March 7th. JPMorgan Chase & Co. dropped their price target on shares of Cooper Companies from $120.00 to $110.00 and set an “overweight” rating on the stock in a research report on Friday, March 7th. Needham & Company LLC reiterated a “hold” rating on shares of Cooper Companies in a research report on Friday, March 7th. Citigroup cut their price target on Cooper Companies from $115.00 to $110.00 and set a “buy” rating for the company in a research note on Friday, March 7th. Finally, BNP Paribas raised Cooper Companies to a “hold” rating in a report on Thursday, March 13th. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, Cooper Companies has an average rating of “Moderate Buy” and a consensus target price of $110.25.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.